Gabriela Lavezzari

Experience

• 

  Executive Council for Leading Change (ECLC)

  Member

  Mar 2025 - Present

  The Executive Council for Leading Change is an invite-only member group where leaders share approaches and insights on business change.

• 

  GSK

  Head, R&D Digital Transformation & Innovation

  May 2024 - Present

  GSK researches, develops, and manufactures innovative pharmaceuticals, vaccines, and consumer healthcare products.

  • Shaped and executed digital health strategy, enabling clinical development and supporting market access across the therapy lifecycle; built a high-performing team within six months.
  • Identified, designed, and implemented scalable digital solutions that improved clinical development efficiency, with sustainable operating models adopted enterprise-wide.
  • Defined and prioritized digital health opportunity areas that strengthened study design, patient engagement, and evidence generation.
  • Established repeatable governance frameworks for embedding digital health and technology solutions, driving consistent innovation.
• 

  GSK

  Chief Of Staff to GSK CMO & SVP of Global Medical, Regulatory, Quality

  Sep 2021 - Apr 2024

  • Championed R&D strategic planning and roadmap execution, aligning priorities, resources, and decision-making across global functions.
  • Delivered real-time visibility to leadership with enterprise R&D and portfolio performance dashboards, improving progress tracking and goal alignment.
  • Led organizational communications and executive reporting, including town halls and leadership updates, ensuring cohesive operation alignment.
• 

  GSK

  Head, Global R&D Policy

  Mar 2020 - Oct 2021

  • Built and led GSK’s Global R&D Policy function, shaping policy strategy, governance, and alignment across all relevant sectors.
  • Served as primary liaison to FDA and international regulators, influencing emerging policy direction through strategic relationship building.
  • Led policy-driven transformation initiatives, demonstrating high collaboration and leadership across global teams.
• 

  GSK

  Sr. Director, US R&D Policy

  Aug 2018 - Mar 2020

• Independent

  Principal

  Feb 2018 - Jul 2018

  Independent is a business development and strategy consulting firm specializing in sustainable growth for startups and SMEs.

• 

  Biocerna

  SVP Business Development

  Apr 2017 - Mar 2018

  Biocerna is a clinical diagnostic laboratory focused on assay development and clinical testing support for improved patient care.

• 

  Duke University

  Research Director, Duke-Robert J. Margolis, MD Center for Health Policy

  Mar 2016 - Apr 2017

  Duke University is a world-renowned educational institution offering transformative academic and research experiences.

  • Led policy research and strategy to integrate medical products into new alternative payment models, paving the way for innovative healthcare solutions.
  • Collaborated with key external bodies like FDA and CMS to align on policy initiatives, building robust frameworks for healthcare policy modernization.
  • Spearheaded strategic planning and execution, securing multimillion-dollar funding to expand research capabilities and impact.
• 

  PhRMA

  AVP, Science & Regulatory Advocacy

  Jul 2012 - Mar 2016

  PhRMA represents biopharmaceutical companies, advocating for policies supporting innovation and patient access to medicines.

  • Developed strategic relationships with regulatory agencies such as the FDA and NIH to promote PhRMA's scientific initiatives.
  • Led initiatives aimed at positioning PhRMA as a top source of scientific expertise, fostering an environment that supports medical innovation.
  • Acted as lead on projects related to major industry legislative initiatives (e.g., PDUFA, 21st Century Cures), driving strategic advocacy efforts.
• 

  Express Scripts by Evernorth

  Director, Extramural Development

  Oct 2009 - Jul 2012

  Express Scripts makes prescription drug use safer and more affordable through extensive pharmaceutical care and services.

  • Led the establishment of a real-world clinical utility and cost effectiveness center for personalized medicine products.
  • Enhanced market access and uptake by designing patient-centric programs, elevating Express Scripts' position in the personalized medicine space.
  • Developed innovative personalized medicine programs, securing contracts with diagnostic and pharmaceutical companies.
• 

  Theranostics Health, Inc

  Lab Director

  Jul 2007 - Oct 2009

  Theranostics Health provides proteomics-based diagnostics services and develops tests for personalized cancer therapies.

• Social & Scientific Systems

  Lab Specialist

  May 2006 - Jul 2007

  Social & Scientific Systems provides research solutions for health-related challenges globally.

• 

  NIH

  Postdoc

  Nov 2001 - May 2006

  The National Institutes of Health is the largest public funder of biomedical research, advancing medical knowledge and improving health.

• 

  Georgetown University

  Postdoc

  Sep 2000 - Nov 2001

  Georgetown University is an academic institution dedicated to creating global leaders through rigorous scholarship and transformative experiences.